Traduction de «required to deal with all » (Néerlandais → Français) :

The R&D (research and development) department is required to deal with all relevant applications for clinical trials.
The R&D (research and development) department is required to deal with all relevant applications for clinical trials.

The inspection units also support the Judicial Authority and are, in addition to their control and inspection tasks, responsible for dealing with and investigating any complaints relating to the legal requirements on medicines and/or health products.
The inspection units also support the Judicial Authority and are, in addition to their control and inspection tasks, responsible for dealing with and investigating any complaints relating to the legal requirements on medicines and/or health products.

Compliance with the European directives on electronic submissions Compliance with the European directives requires a number of objectives to be achieved: ●● Arriving at a functional vision of communication standards with EMEA and the Member States in partnership with the industry and in line with European legislation ●● Standard project management, with important steps that are sponsored/supported by the Member States: first developing an IT infrastructure and then starting on a highly secure network followed by so-called “proofs of concept” in each field ●● Success depends above all on the FAHMP’s
Compliance with the European directives on electronic submissions Compliance with the European directives requires a number of objectives to be achieved: ●● Arriving at a functional vision of communication standards with EMEA and the Member States in partnership with the industry and in line with European legislation ●● Standard project management, with important steps that are sponsored/supported by the Member States: first developing an IT infrastructure and then starting on a highly secure network followed by so-called “proofs of concept” in each field ●● Success depends above all on the FAHMP’s

There is a set of minutes of “A points”, which may be consulted via intranet by all FAMHP employees, and one of the “B points”, which deals with more confidential and/or personal topics and is for that reason, only circulated to the members of the executive board.
There is a set of minutes of “A points”, which may be consulted via intranet by all FAMHP employees, and one of the “B points”, which deals with more confidential and/or personal topics and is for that reason, only circulated to the members of the executive board.

This information is meant for all, as anyone can find themselves in a situation where they have to deal with the issue of suicide at their own level and within their own surroundings.
Ces informations s’adressent à tous, dans la mesure où chacun peut à son niveau, dans son cadre de vie, être questionné par la problématique suicidaire.

This explains the setting up of a new structure using messages of very general interest (15 questions - 15 answers) aimed at all listeners belonging to all age groups, and especially isolated people, who do not read papers or magazines and do not listen to broadcasts about depression, which require a personal choice and selection to begin with.
Ceci explique une structure nouvelle utilisant des messages d’intérêt très général (15 questions – 15 réponses) à destination de tous les auditeurs de tous âges dont notamment les personnes isolées, celles qui ne lisent pas les journaux et magazines, qui ne suivent pas non plus les émissions consacrées à la dépression qui appellent à un choix et une sélection personnelle au départ.

The key elements of this ambition are, firstly, the provision of efficient and high-quality services and, secondly, compliance with all the legal requirements imposed on the FAMHP (taking account of the revised Belgian pharmaceutical legislation and the European Directives).
The key elements of this ambition are, firstly, the provision of efficient and high-quality services and, secondly, compliance with all the legal requirements imposed on the FAMHP (taking account of the revised Belgian pharmaceutical legislation and the European Directives).